A landmark global epidemiological study recently confirmed what infectious disease specialists have long understood: approximately one in eight new cancer cases worldwide are attributable to preventable infections. The pathogens are well-characterized—Helicobacter pylori, human papillomavirus, hepatitis B and C viruses, Epstein-Barr virus, and others—and the causal pathways are established through decades of rigorous molecular and population-based research. The interventions exist: effective vaccines, antimicrobial therapies, and screening protocols that could prevent thousands of deaths annually.
Yet this epidemiological triumph feels increasingly hollow when viewed through the lens of global health equity.
The uncomfortable truth is that infection-attributable cancers cluster disproportionately in low- and middle-income countries, where the very public health infrastructure needed to translate this knowledge into prevention is fragmented, underfunded, or absent entirely. A patient in rural Georgia, Sub-Saharan Africa, or South Asia may live in a region where HPV vaccination programs remain nascent, where H. pylori screening is unavailable outside tertiary centers, and where hepatitis B prevention relies on childhood immunization schedules that struggle with cold-chain logistics. Meanwhile, the epidemiological data documenting preventable cancer burden accumulates in high-impact journals read primarily by clinicians and policymakers in high-income nations.
This is not a failure of epidemiology. The research is rigorous, the findings are actionable, and the public health implications are clear. Rather, it is a failure of implementation systems—and more fundamentally, a failure of global health governance to match prevention capacity with disease burden.
Consider the HPV vaccine story. Since its introduction in the mid-2000s, HPV vaccination has driven cervical cancer incidence down dramatically in countries with sustained, well-funded national immunization programs. Australia, for instance, projects the virtual elimination of cervical cancer within decades. Yet in many low-income countries, HPV vaccine coverage remains below 10%, not because the evidence is disputed, but because supply chains are unreliable, trained personnel are scarce, and competing health emergencies demand finite resources.
Similarly, H. pylori eradication—a simple, inexpensive antimicrobial intervention—could prevent gastric cancer in high-prevalence regions. Yet systematic screening and treatment programs remain absent in many countries where the infection burden is highest. The reasons are predictable: lack of diagnostic capacity, antimicrobial resistance concerns without stewardship infrastructure, and absence of integrated primary care systems to deliver treatment at scale.
The epidemiological insight—that infections cause one in eight cancers—should trigger urgent action on prevention. Instead, it often triggers academic citations and policy briefs that sit unimplemented on ministry desks.
What is required is not more epidemiology. It is coordinated, resource-intensive implementation science and health systems strengthening in the exact regions bearing the heaviest burden. This means:
First, sustained funding mechanisms for vaccine procurement and cold-chain infrastructure in low-income countries—not through charity, but as a matter of global health justice. The cost of preventing one cervical cancer through HPV vaccination is a fraction of the direct and indirect costs of treating advanced disease.
Second, decentralized diagnostic and treatment capacity for infections linked to cancer. Rapid diagnostic tests for H. pylori, HPV, and hepatitis viruses must be deployed to district hospitals and primary health centers, not reserved for capital cities.
Third, antimicrobial stewardship programs embedded within prevention frameworks. Treating infection-driven cancers requires surveillance of resistance patterns and rational prescribing guidelines tailored to local epidemiology—not blanket antibiotic distribution or therapeutic nihilism.
Fourth, honest assessment of trade-offs. In resource-constrained settings, infection-driven cancer prevention competes with maternal health, infectious disease control, and management of noncommunicable diseases. Public health decision-making must be explicit about these trade-offs rather than pretending that all interventions are simultaneously feasible.
As Editor-in-Chief of this journal, I see regularly the flow of high-quality epidemiological research demonstrating preventable disease burden in low-income populations. The research itself is often conducted by scholars from those very regions, yet implementation remains distant from where the evidence originates. This asymmetry—between knowledge generation and implementation capacity—represents a structural inequity in global health.
The finding that one in eight cancers are infection-driven is powerful. But power without the means to act is merely an indictment of our global health system’s priorities. Until we match epidemiological insight with genuine resource commitment to implementation in low-income countries, we risk treating prevention statistics as intellectual exercises rather than calls to action.
The infections are preventable. The cancers need not occur. We have the tools. We lack the will to deploy them equitably.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
